Today, Dr. Scott Struthers talks to PWN about paltusotine, their new once-a-day oral drug candidate, which recently completed phase 3 of the clinical trial.
During these trying times, work continues, even at a faster pace, for new drugs and therapies for pituitary patients. From the J D Faccinetti, co-founder – We recently caught up with Crinetics Pharmaceuticals chairman Dr.
From JD Faccinetti, co-founder and chief editor – I like to ramble, so here it goes. I was musing about how unique and essential this little gland is—the size of a pea, the pituitary runs almost
San Diego, California-based Crinetics Pharmaceutical announced today that its novel investigational drug paltusotine maintained IGf-1 levels in patients who switched from monthly injectables
In a press release today, San Diego, California based Crinetics Pharmaceuticals reports positive results from their Phase Two trial of PALTUSOTINE (the former CRN00808). This is a new oral medication to treat acromegaly and neuroendocrine
This is the first in a series of 6 podcasts on the ins and outs of drug development. In it, we discuss the journey that a promising molecule takes to develop into a life-saving medication and
The perception that scientists and healthcare professionals do not understand what patients go through when dealing with disease, particularly chronic disease, was the focus of a refreshing exercise this past month at Crinetics Pharmaceuticals. To
As we reported earlier this year, the acromegaly new drug development world has seen very exciting activity. Several studies are in the pipeline for oral therapies. Today, San Diego California based Crinetics Pharmaceuticals announced a new
Insurance rumblings: As far as we can tell these are not widespread tactics but some insurance companies are limiting the use of drug copays that previously counted against deductibles. This is particularly troublesome for rare
A conversation with Dr. Scott Struthers, Founder, and CEO of Crinetics Pharmaceutical. These are exciting times in the world of endocrine drug discovery and development, particularly for Acromegaly and Cushing’s patients. In today’s podcast we